At the 2023 BIO-Europe conference, In Vivo sat down with Ipsen’s EVP and chief business officer, Philippe Lopes-Fernandes, to discuss the company’s business development strategy and future goals.
“We are not looking for a cheap deal, we are looking for the right deal.” This is the mindset for Ipsen’s chief business officer, Philippe Lopes-Fernandes. He is leading the charge for Ipsen’s deal-making strategy, as the company seeks growth in a disrupted pharma market.
Ipsen, a pureplay pharma company, does not have an internal discovery machine. It uses an external development model. “We are...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Exec summary XXXXXXX
Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
